ArticleMedicine2016
Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis.European journal of pediatrics · 2026Pooled it
- Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.Scientific reports · 2017Trial
- The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Infantile hemangiomas: a dermatologist's perspective.European journal of pediatrics · 2024Review
- Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.The Journal of clinical investigation · 2022Article
- Management of infantile hemangiomas: Recent advances.Frontiers in oncology · 2022Review
- Treatment of haemangiomas using propranolol in paediatric patients: a retrospective cohort study.Postepy dermatologii i alergologii · 2020Article
- Progress in the treatment of infantile hemangioma.Annals of translational medicine · 2019Review
- Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier.Frontiers in neuroscience · 2019Article
- Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.Scientific reports · 2018Article
- [Research progresses in the pathogenesis, diagnosis and treatment of infantile hemangioma with PHACE syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Review
- [Infantile hemangioma of the eyelid].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Article
- Quality of life in children with infantile hemangioma: a case control study.Health and quality of life outcomes · 2017Article
- Advances in the Medical Management of Vascular Anomalies.Seminars in interventional radiology · 2017Review
- When to stop propranolol for infantile hemangioma.Scientific reports · 2017Article
- Erratum: Medicine, Volume 95, Issue 24: Erratum.Medicine · 2016Article
- Oral Atenolol versus Propranolol in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis.Journal of Indian Association of Pediatric SurgeonsArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Propranolol, a lipophilic nonselective β-blocker, has recently been reported to be the treatment of choice for select types of infantile hemangiomas (IHs). Atenolol is a hydrophilic, selective β1-blocker and therefore may be not associated with side effects attributable to β2-adrenergic receptor blockade and lipophilicity. However, the efficacy and safety of atenolol in the treatment of IH are poorly understood. The aim of this study was to evaluate the efficacy and safety of atenolol in the treatment of proliferating IHs.A study of 76 infants between the ages of 5 to 20 weeks with superficial or mixed IH was conducted between August 2013 and March 2015. Oral atenolol was administered in a progressive schedule to 1 mg/kg per day in a single dose. Efficacy was assessed using the Hemangioma Activity Score (HAS) at weeks 0, 1, 4, 12, and 24. Safety was evaluated at weeks 0, 1, 4, 8, 12, 16, 20, and 24.In total, 70 patients completed 24 weeks of treatment. IH growth abruptly stopped for 93.4% of patients within the fourth week of treatment with atenolol. In ulcerated IHs, complete healing of the ulcerations occurred in an average treatment time of 5.5 weeks. Atenolol treatment promoted dramatic decreases in HAS scores after week 1. An "excellent" treatment response (compete or nearly complete resolution of the IH) was observed in 56.5% of patients at week 24. No significant hypoglycemia, bronchospasm, bradycardia, or hypotension occurred. The most common adverse event was diarrhea, followed by agitation and sleep disturbance.This study demonstrated that atenolol was effective and safe at a dose of 1 mg/kg per day for 24 weeks in the treatment of proliferating IHs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.